Advertisement

A State Dependence of the Response to N-Methyl-D-Aspartate Receptor Antagonism

  • Robert W. Greene
    Correspondence
    Address correspondence to Robert W. Greene, M.D., Ph.D., Departments of Psychiatry and Neuroscience, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390
    Affiliations
    Departments of Psychiatry and Neuroscience, UT Southwestern Medical Center, Dallas, Texas.

    Department of Veterans Affairs, Dallas, Texas.
    Search for articles by this author
      The best pharmacobehavioral model for psychosis associated with schizophrenia is the N-methyl-D-aspartate receptor (NMDAR) antagonist model (
      • Javitt D.C.
      • Zukin S.R.
      Recent advances in the phencyclidine model of schizophrenia.
      ,
      • Krystal J.H.
      • Karper L.P.
      • Seibyl J.P.
      • Freeman G.K.
      • Delaney R.
      • Bremner J.D.
      • et al.
      Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
      ). The NMDAR antagonists provide an invaluable tool for the investigation of cellular and circuit mechanisms responsible for a psychotic state that so closely resembles that of schizophrenia.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Javitt D.C.
        • Zukin S.R.
        Recent advances in the phencyclidine model of schizophrenia.
        Am J Psychiatry. 1991; 148: 1301-1308
        • Krystal J.H.
        • Karper L.P.
        • Seibyl J.P.
        • Freeman G.K.
        • Delaney R.
        • Bremner J.D.
        • et al.
        Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
        Arch Gen Psychiatry. 1994; 51: 199-214
        • Zhang Y.
        • Llinas R.R.
        • Lisman J.E.
        Inhibition of NMDARs in the nucleus reticularis of the thalamus produces delta frequency bursting.
        Front Neural Circuits. 2009; 3: 20
        • Zhang Y.
        • Yoshida T.
        • Katz D.B.
        • Lisman J.E.
        NMDAR antagonist action in thalamus imposes delta oscillations on the hippocampus.
        J Neurophysiol. 2012; 107: 3181-3189
        • Troyano-Rodriguez E.
        • Lladó-Pelfort L.
        • Santana N.
        • Teruel-Marti V.
        • Celada P.
        • Artigas F.
        Phencyclidine inhibits the activity of thalamic reticular gamma-aminobutyric acidergic neurons in rat brain.
        Biol Psychiatry. 2014; 76: 937-945
        • Ushimaru M.
        • Ueta Y.
        • Kawaguchi Y.
        Differentiated participation of thalamocortical subnetworks in slow/spindle waves and desynchronization.
        J Neurosci. 2012; 32: 1730-1746
        • Steriade M.
        • McCormick D.A.
        • Sejnowski T.J.
        Thalamocortical oscillations in the sleeping and aroused brain.
        Science. 1993; 262: 679-685
        • Grunze H.C.
        • Rainnie D.G.
        • Hasselmo M.E.
        • Barkai E.
        • Hearn E.F.
        • McCarley R.W.
        • et al.
        NMDA-dependent modulation of CA1 local circuit inhibition.
        J Neurosci. 1996; 16: 2034-2043
        • Monti J.M.
        • Monti D.
        Sleep disturbance in schizophrenia.
        Int Rev Psychiatry. 2005; 17: 247-253